Resources
News

Michael K. Fee to Lead Verrill’s Health Care and Life Sciences Defense Practice

January 22, 2020 Press Releases

(January 22, 2020) – Verrill is pleased to welcome Michael K. Fee to the firm’s Boston office as a Partner in its nationally recognized Health Care & Life Sciences Group and as the leader of Verrill’s health care and life sciences defense practice.

Fee brings extensive experience with internal investigations, the defense of government investigations and enforcement actions, and in handling all types of health care fraud and abuse matters. He is particularly experienced in matters involving academic medical centers, hospitals, physician groups, and other providers, as well as universities, medical device companies, pharmaceutical manufacturers, PBMs, and health insurers. Fee is also experienced in the areas of securities enforcement, the U.S. Foreign Corrupt Practices Act, export and trade regulation, public corruption, and campaign finance law. He has defended numerous cases brought under the U.S. Civil False Claims Act, litigating these cases against the government and private relators successfully in federal district court and the federal courts of appeals. He also uses his defense experience to assist clients with the design and implementation of compliance systems. Fee also represents clients in complex civil litigation.

“The firm is pleased to welcome Michael to our Health Care & Life Sciences Group, which continues its trajectory of growth and expansion. The practice synergies between Michael and our existing team will only serve to strengthen the high quality, high value services we provide to our clients,” stated K.C. Jones, Managing Partner of Verrill.

Most recently, Fee was a partner and member of the White Collar Defense and Investigations Practice Group and the Litigation and Trial Department in Latham & Watkins, LLP’s Boston office. Prior to that, Fee was a partner and Co-Practice Group Leader of the Government Enforcement and White Collar Practice Group in Ropes & Gray, LLP’s Boston office. Earlier in his career, he served as a prosecutor with the Public Integrity Section of the Criminal Division, United States Department of Justice (DOJ) in Washington, D.C., where he investigated and prosecuted public corruption cases. While at the DOJ, he also served as a Special Assistant United States Attorney in the Office of the U.S. Attorney for the Eastern District of Virginia (Alexandria Division) prosecuting various crimes on federal lands, drug offenses, fraud and homicide.

“For years we have known that many of our large institution and company clients seek Michael’s guidance on their most significant government investigations and enforcement matters. We are thrilled to have him join our team,” explained Andrew P. Rusczek, Chair of Verrill’s Health Care & Life Sciences Group. “His deep experience, smarts, and legal savvy will help us further our core goal of providing unsurpassed value to our health care and life sciences clients across the country.”

Fee received his bachelor’s degree from Boston College and earned his law degree from Boston College Law School. Following law school he clerked for the Honorable A. David Mazzone (D. Mass).

Firm Highlights

Publication/Podcast

Due to COVID-19, Federal Agencies Relax Requirements Regarding the Provision of Telehealth Services

In the past few days, in an effort to help keep Medicare beneficiaries healthy during the COVID-19 pandemic, key federal agencies within the U.S. Department of Health and Human Services (“HHS”) and the U.S...

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

Publication/Podcast

COVID-19 Expanded Access Template

We are aware that many companies and health care providers are working to expedite the transfer of investigational drugs that may be helpful in treating patients suffering from COVID-19. Although these expanded access arrangements...

Publication/Podcast

Responsible Research During the COVID-19 Pandemic

Publication/Podcast

Updated FDA COVID-19 Guidance for Conduct of Clinical Trials

On March 27, 2020, the U.S. Food & Drug Administration (“FDA”) updated its prior guidance on the “ Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic ,” with an appendix adding a...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Matter

Common Rule

Guided multiple clients through the implementation of the revised HHS regulations (the "Common Rule"), including reviewing and revising policies and procedures, and assisting with institutional approaches to implementation.

Matter

FDA Advertising/Promotion

Presented to senior executives and other management of a start-up pharmaceutical company on complying with the FDA advertising and promotion requirements pre- and post-launch.

Publication/Podcast

COVID-19: FDA Clinical Trial Guidance

On March 18, 2020, the U.S. Food & Drug Administration (“FDA”) published guidance for clinical trial sponsors, investigators, and institutional review boards (“IRBs”) on conducting clinical trials in the midst of the COVID-19 pandemic...